Contrary to GLP-1R mono-agonist, whose efficacy is limited by dose-dependent gastrointestinal events, the new triple agonists can simultaneously increase energy expenditure, reduce food intake, and improve glucose control by engaging all three receptors at once
Scientific Data: In the SURPASS trials, tirzepatide showed higher rates of gastrointestinal side effects compared to semaglutide, but these were generally temporary and resolved as treatment continued
doi: 10.1517/17425255.2014.920823
Dissection of the intracellular pathways in hepatocytes suggests a role for Jun kinase and IFN regulatory factor-1 in Con A-induced liver failure
Osteoarthritis Osteoarthritis (OA), particularly of the knee, is the most prevalent form of arthritis, characterized by chronic pain and physical disability [36, 38]